Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Fate Therapeutics (FATE) over the last 13 years, with Q3 2025 value amounting to $6.6 million.

  • Fate Therapeutics' Treasury Shares rose 708.04% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 708.04%. This contributed to the annual value of $6.2 million for FY2024, which is 10273.7% up from last year.
  • Per Fate Therapeutics' latest filing, its Treasury Shares stood at $6.6 million for Q3 2025, which was up 708.04% from $7.0 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Treasury Shares registered a high of $7.2 million during Q1 2025, and its lowest value of $1.5 million during Q1 2021.
  • Over the past 5 years, Fate Therapeutics' median Treasury Shares value was $4.0 million (recorded in 2021), while the average stood at $4.6 million.
  • In the last 5 years, Fate Therapeutics' Treasury Shares soared by 28499.34% in 2022 and then tumbled by 4771.91% in 2023.
  • Quarter analysis of 5 years shows Fate Therapeutics' Treasury Shares stood at $4.0 million in 2021, then surged by 46.25% to $5.9 million in 2022, then plummeted by 47.72% to $3.1 million in 2023, then skyrocketed by 102.74% to $6.2 million in 2024, then increased by 6.97% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $7.0 million for Q2 2025, and $7.2 million during Q1 2025.